DD102584A5 - - Google Patents

Info

Publication number
DD102584A5
DD102584A5 DD168904A DD16890473A DD102584A5 DD 102584 A5 DD102584 A5 DD 102584A5 DD 168904 A DD168904 A DD 168904A DD 16890473 A DD16890473 A DD 16890473A DD 102584 A5 DD102584 A5 DD 102584A5
Authority
DD
German Democratic Republic
Application number
DD168904A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH229972A external-priority patent/CH574247A5/de
Application filed filed Critical
Publication of DD102584A5 publication Critical patent/DD102584A5/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35Corticotropin [ACTH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
DD168904A 1972-02-17 1973-02-16 DD102584A5 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH229972A CH574247A5 (en) 1972-02-17 1972-02-17 Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
CH1782972 1972-12-07

Publications (1)

Publication Number Publication Date
DD102584A5 true DD102584A5 (xx) 1973-12-20

Family

ID=25690055

Family Applications (1)

Application Number Title Priority Date Filing Date
DD168904A DD102584A5 (xx) 1972-02-17 1973-02-16

Country Status (18)

Country Link
US (1) US3869549A (xx)
JP (1) JPS4892516A (xx)
AR (1) AR197116A1 (xx)
AT (1) AT335615B (xx)
AU (1) AU472655B2 (xx)
BE (1) BE795516A (xx)
CS (1) CS172967B2 (xx)
DD (1) DD102584A5 (xx)
DE (1) DE2306075A1 (xx)
DK (1) DK134098B (xx)
ES (1) ES411655A1 (xx)
FR (1) FR2181734B1 (xx)
GB (1) GB1418408A (xx)
IE (1) IE37151B1 (xx)
IL (1) IL41416A (xx)
NL (1) NL7300953A (xx)
PL (1) PL90318B1 (xx)
SE (1) SE7600435L (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2254043C2 (de) * 1972-11-04 1985-01-24 Hoechst Ag, 6230 Frankfurt LH-Releasing Hormon zur nasalen Applikation
DE2254061A1 (de) * 1972-11-04 1974-05-16 Hoechst Ag Lh-releasing hormon zur nasalen applikation
JPS528375B2 (xx) * 1973-07-02 1977-03-09
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
JPS55118415A (en) * 1979-02-28 1980-09-11 Pii Papahadojiyopo Dometoriosu Method of encapsulating biologically active substance in lipoid cell
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5086041A (en) * 1984-10-04 1992-02-04 Monsanto Company Methods of using prolonged release somatotropin compositions
DE3502099A1 (de) * 1985-01-23 1986-08-07 Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold Therapeutisches, peptid- und/oder aminosaeurehaltiges mittel
US4650854A (en) * 1985-06-06 1987-03-17 Usv Pharmaceutical Corporation Amide analogs of calcitonin
US4804742A (en) * 1985-06-06 1989-02-14 Rorer Pharmaceutical Corporation Amide analogs of calcitonin
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
IL79765A (en) * 1985-08-23 1992-02-16 Lilly Co Eli Injectable sustained release formulations of bovine somatotropin
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
KR19990071255A (ko) 1998-02-28 1999-09-15 성재갑 소마토트로핀과 비타민의 합제 조성물
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2005329255B2 (en) * 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US8968786B2 (en) 2007-06-22 2015-03-03 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5623406B2 (ja) 2008-09-17 2014-11-12 キアズマ インコーポレイテッド 医薬組成物および関連する送達方法
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス,インコーポレイティド インプラントの設置及び撤去システム
CL2016000217A1 (es) * 2016-01-27 2016-07-01 Farmacologia En Aquacultura Veterinaria Fav S A Nueva composición veterinaria inyectable para la sincronización del desove en peces
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE950676C (de) * 1948-01-06 1956-10-11 Bristol Lab Inc Verfahren zur Herstellung eines injizierbaren Arzneimittels
DE920148C (de) * 1951-03-31 1954-11-15 Nyegaard & Co As Verfahren zur Herstellung von Adrenocorticotrophin-Praeparaten mit verlaengerter Wirkungsdauer
US2944940A (en) * 1956-01-16 1960-07-12 Armour & Co Adrenocorticotrophin and zinc composition
US2945783A (en) * 1957-06-20 1960-07-19 Reheis Company Inc Aluminum protein antacid and process of making

Also Published As

Publication number Publication date
SE7600435L (sv) 1976-01-16
AU5218973A (en) 1974-08-15
PL90318B1 (xx) 1977-01-31
GB1418408A (en) 1975-12-17
AR197116A1 (es) 1974-03-15
AT335615B (de) 1977-03-25
CS172967B2 (xx) 1977-01-28
DE2306075A1 (de) 1973-08-23
NL7300953A (xx) 1973-08-21
FR2181734A1 (xx) 1973-12-07
ES411655A1 (es) 1976-09-01
IL41416A (en) 1976-03-31
DK134098B (da) 1976-09-13
DK134098C (xx) 1977-02-21
AU472655B2 (en) 1976-06-03
IE37151L (en) 1973-08-17
US3869549A (en) 1975-03-04
IL41416A0 (en) 1973-03-30
BE795516A (fr) 1973-08-16
IE37151B1 (en) 1977-05-11
JPS4892516A (xx) 1973-11-30
ATA140873A (de) 1976-07-15
FR2181734B1 (xx) 1975-10-10

Similar Documents

Publication Publication Date Title
FR2181734B1 (xx)
JPS5254451Y2 (xx)
FR2159137A5 (xx)
JPS4945179U (xx)
JPS5217452B2 (xx)
JPS4977204A (xx)
JPS5432952B2 (xx)
JPS5135996B2 (xx)
JPS4915378U (xx)
JPS4946094A (xx)
JPS4931662A (xx)
JPS5414056B2 (xx)
JPS4924646A (xx)
JPS4940514U (xx)
JPS48106766U (xx)
JPS4928886U (xx)
JPS4931682A (xx)
BG25981A3 (xx)
CH569427A5 (xx)
BG22277A1 (xx)
BG21095A1 (xx)
CH590279A5 (xx)
BG20609A3 (xx)
CH592473A5 (xx)
BG20575A3 (xx)